Differential regulation of GluA1 expression by ketamine and memantine

Behavioural Brain Research

Volumn 316, Issue , 2017, Pages 152-159

  Zhang, Ke ^a   Yamaki, Vitor Nagai ^a   Wei, Zhisheng ^b   Zheng, Yu ^b   Cai, Xiang ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

AMPA receptor; GluA1 Ser845; Ketamine; Major depressive disorder; Memantine

Indexed keywords

GLUTAMATE A1; IONOTROPIC RECEPTOR; KETAMINE; MAMMALIAN TARGET OF RAPAMYCIN; MEMANTINE; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; AMINO ACID RECEPTOR BLOCKING AGENT; AMPA RECEPTOR; BENZYLAMINE DERIVATIVE; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 1; PHOSPHINIC ACID DERIVATIVE; PICROTOXIN; [3 (3,4 DICHLOROBENZYLAMINO)PROPYL](DIETHOXYMETHYL)PHOSPHINIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME REGULATION; FEMALE; FORCED SWIM TEST; HIPPOCAMPAL CA1 REGION; INCUBATION TIME; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SINGLE DRUG DOSE; SYNAPTIC TRANSMISSION; ANIMAL; DEPRESSION; DISEASE MODEL; DRUG EFFECTS; EXCITATORY POSTSYNAPTIC POTENTIAL; GENE EXPRESSION REGULATION; HIPPOCAMPUS; IN VITRO STUDY; METABOLISM; PHOSPHORYLATION; PSYCHOLOGY; SPRAGUE DAWLEY RAT; SWIMMING; SYNAPTOSOME;

ANIMALS; BENZYLAMINES; DEPRESSION; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; EXCITATORY POSTSYNAPTIC POTENTIALS; GABA ANTAGONISTS; GENE EXPRESSION REGULATION; HIPPOCAMPUS; IN VITRO TECHNIQUES; KETAMINE; MEMANTINE; PHOSPHINIC ACIDS; PHOSPHORYLATION; PICROTOXIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; SWIMMING; SYNAPTIC TRANSMISSION; SYNAPTOSOMES;

EID: 84985905502     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2016.09.002     Document Type: Article

References (39)

1. [1] aan het Rot, M., Collins, K.A., Murrough, J.W., Perez, A.M., Reich, D.L., Charney, D.S., Mathew, S.J., Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol. Psychiatry 67 (2010), 139–145.
2. [2] Autry, A.E., Adachi, M., Nosyreva, E., Na, E.S., Los, M.F., Cheng, P.F., Kavalali, E.T., Monteggia, L.M., NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475 (2011), 91–95.
3. [3] Banke, T.G., Bowie, D., Lee, H., Huganir, R.L., Schousboe, A., Traynelis, S.F., Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase. J. Neurosc. 20 (2000), 89–102.
4. [4] Belmaker, R.H., Agam, G., Major depressive disorder. N. Engl. J. Med. 358 (2008), 55–68.
5. [5] Browne, C.A., Lucki, I., Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front. Pharmacol., 4, 2013, 161.
6. [6] Cai, X., Kallarackal, A.J., Kvarta, M.D., Goluskin, S., Gaylor, K., Bailey, A.M., Lee, H.K., Huganir, R.L., Thompson, S.M., Local potentiation of excitatory synapses by serotonin and its alteration in rodent models of depression. Nat. Neurosci. 16 (2013), 464–472.
7. [7] Cai, X., Liang, C.W., Muralidharan, S., Kao, J.P., Tang, C.M., Thompson, S.M., Unique roles of SK and Kv4.2 potassium channels in dendritic integration. Neuron 44 (2004), 351–364.
8. [8] Chen, H.S., Lipton, S.A., Pharmacological implications of two distinct mechanisms of interaction of memantine with N-methyl-D-aspartate-gated channels. J. Pharmacol. Exp. Ther. 314 (2005), 961–971.
9. [9] Cull-Candy, S.G., Leszkiewicz, D.N., Role of distinct NMDA receptor subtypes at central synapses. Sci. STKE: Signal Transduction Knowl. Environ., 2004, 2004, re16.
10. [10] Derkach, V., Barria, A., Soderling, T.R., Ca2+/calmodulin-kinase II enhances channel conductance of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate type glutamate receptors. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 3269–3274.
11. [11] Dingledine, R., Borges, K., Bowie, D., Traynelis, S.F., The glutamate receptor ion channels. Pharmacol. Rev. 51 (1999), 7–61.
12. [12] Duman, R.S., Li, N., Liu, R.J., Duric, V., Aghajanian, G., Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62 (2012), 35–41.
13. [13] Gideons, E.S., Kavalali, E.T., Monteggia, L.M., Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 8649–8654.
14. [14] Hsu, K.S., Ho, W.C., Huang, C.C., Tsai, J.J., Prior short-term synaptic disinhibition facilitates long-term potentiation and suppresses long-term depression at CA1 hippocampal synapses. Eur. J. Neurosci. 11 (1999), 4059–4069.
15. [15] Ibrahim, L., Diazgranados, N., Franco-Chaves, J., Brutsche, N., Henter, I.D., Kronstein, P., Moaddel, R., Wainer, I., Luckenbaugh, D.A., Manji, H.K., Zarate, C.A. Jr., Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacol.: Off. Pub. Am. Coll. Neuropsychopharmacol. 37 (2012), 1526–1533.
16. [16] Kashiwagi, K., Masuko, T., Nguyen, C.D., Kuno, T., Tanaka, I., Igarashi, K., Williams, K., Channel blockers acting at N-methyl-D-aspartate receptors: differential effects of mutations in the vestibule and ion channel pore. Mol. Pharmacol. 61 (2002), 533–545.
17. [17] Kishimoto, T., Chawla, J.M., Hagi, K., Zarate, C.A., Kane, J.M., Bauer, M., Correll, C.U., Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol. Med. 46 (2016), 1459–1472.
18. [18] Kotermanski, S.E., Johnson, J.W., Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine. J. Neurosci. 29 (2009), 2774–2779.
19. [19] Lee, H.K., Barbarosie, M., Kameyama, K., Bear, M.F., Huganir, R.L., Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity. Nature 405 (2000), 955–959.
20. [20] Lenze, E.J., Skidmore, E.R., Begley, A.E., Newcomer, J.W., Butters, M.A., Whyte, E.M., Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study. Int. J. Geriatr. Psychiatry 27 (2012), 974–980.
21. [21] Li, N., Lee, B., Liu, R.J., Banasr, M., Dwyer, J.M., Iwata, M., Li, X.Y., Aghajanian, G., Duman, R.S., mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329 (2010), 959–964.
22. [22] Lu, W., Shi, Y., Jackson, A.C., Bjorgan, K., During, M.J., Sprengel, R., Seeburg, P.H., Nicoll, R.A., Subunit composition of synaptic AMPA receptors revealed by a single-cell genetic approach. Neuron 62 (2009), 254–268.
23. [23] Machado-Vieira, R., Salvadore, G., Diazgranados, N., Zarate, C.A. Jr., Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol. Ther. 123 (2009), 143–150.
24. [24] Marszalek-Grabska, M., Gibula-Bruzda, E., Jenda, M., Gawel, K., Kotlinska, J.H., Memantine improves memory impairment and depressive-like behavior induced by amphetamine withdrawal in rats. Brain Res. 1642 (2016), 389–396.
25. [25] Mathew, S.J., Shah, A., Lapidus, K., Clark, C., Jarun, N., Ostermeyer, B., Murrough, J.W., Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs 26 (2012), 189–204.
26. [26] Monyer, H., Burnashev, N., Laurie, D.J., Sakmann, B., Seeburg, P.H., Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12 (1994), 529–540.
27. [27] Moser, E.I., Krobert, K.A., Moser, M.B., Morris, R.G., Impaired spatial learning after saturation of long-term potentiation. Science 281 (1998), 2038–2042.
28. [28] Nosyreva, E., Szabla, K., Autry, A.E., Ryazanov, A.G., Monteggia, L.M., Kavalali, E.T., Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J. Neurosci. 33 (2013), 6990–7002.
29. [29] Roche, K.W., O'Brien, R.J., Mammen, A.L., Bernhardt, J., Huganir, R.L., Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron 16 (1996), 1179–1188.
30. [30] Ruotolo, F., van der Ham, I.J., Iachini, T., Postma, A., The relationship between allocentric and egocentric frames of reference and categorical and coordinate spatial information processing. Q. J. Exp. Psychol. 64 (2011), 1138–1156.
31. [31] Smith, E.G., Deligiannidis, K.M., Ulbricht, C.M., Landolin, C.S., Patel, J.K., Rothschild, A.J., Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 74 (2013), 966–973.
32. [32] Sneider, J.T., Sava, S., Rogowska, J., Yurgelun-Todd, D.A., A preliminary study of sex differences in brain activation during a spatial navigation task in healthy adults. Percept. Mot. Skills 113 (2011), 461–480.
33. [33] Sutton, M.A., Taylor, A.M., Ito, H.T., Pham, A., Schuman, E.M., Postsynaptic decoding of neural activity: eEF2 as a biochemical sensor coupling miniature synaptic transmission to local protein synthesis. Neuron 55 (2007), 648–661.
34. [34] Thompson, S.M., Kallarackal, A.J., Kvarta, M.D., Van Dyke, A.M., LeGates, T.A., Cai, X., An excitatory synapse hypothesis of depression. Trends Neurosci. 38 (2015), 279–294.
35. [35] Verpelli, C., Piccoli, G., Zibetti, C., Zanchi, A., Gardoni, F., Huang, K., Brambilla, D., Di Luca, M., Battaglioli, E., Sala, C., Synaptic activity controls dendritic spine morphology by modulating eEF2-dependent BDNF synthesis. J. Neurosci. 30 (2010), 5830–5842.
36. [36] Wenthold, R.J., Petralia, R.S., Blahos, J. II, Niedzielski, A.S., Evidence for multiple AMPA receptor complexes in hippocampal CA1/CA2 neurons. J. Neurosci. 16 (1996), 1982–1989.
37. [37] Yang, C., Zhou, Z.Q., Gao, Z.Q., Shi, J.Y., Yang, J.J., Acute increases in plasma mammalian target of rapamycin, glycogen synthase kinase-3beta, and eukaryotic elongation factor 2 phosphorylation after ketamine treatment in three depressed patients. Biol. Psychiatry 73 (2013), e35–36.
38. [38] Zanos, P., Moaddel, R., Morris, P.J., Georgiou, P., Fischell, J., Elmer, G.I., Alkondon, M., Yuan, P., Pribut, H.J., Singh, N.S., Dossou, K.S., Fang, Y., Huang, X.P., Mayo, C.L., Wainer, I.W., Albuquerque, E.X., Thompson, S.M., Thomas, C.J., Zarate, C.A. Jr., Gould, T.D., NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533 (2016), 481–486.
39. [39] Zarate, C.A. Jr., Singh, J.B., Carlson, P.J., Brutsche, N.E., Ameli, R., Luckenbaugh, D.A., Charney, D.S., Manji, H.K., A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63 (2006), 856–864.